Individual InvestorsEmployee Shareholders Institutional InvestorsPrivate Companies Accredited InvestorsSeed & Angel InvestorsAsset Managers & Hedge FundsFamily OfficesVenture Capital FirmsWealth Managers & RIAsWho We Serve Trading Data Liquidity Programs Retirement Individual InvestingForge MarketplaceFind new private company investment opportunities​Browse CompaniesInstitutional TradingForge ProTrade private companies with Forge’s institutional brokerage tool​Forge PriceA proprietary indicative price, calculated daily, for approximately 200 pre-IPO companiesForge DataAnalyze private markets via Forge’s intuitive web application​Forge Private Market Index​Monitor a benchmark for actively traded private companies ​Forge Accuidity Private Market Index​Invest in an institutionally-managed diversified basket of private companies (QPs only)​Liquidity ProgramsRetain and reward employees with company-sponsored liquidity solutions like tender offers and customized programsSelf-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRAWhat We Do All Insights Reports and highlights News and trends Private market education Tips and tutorials Forge Investment OutlookPrivate Market UpdatesIPO calendarPrivate Magnificent 7Emerging trendsPrivate company newsUpcoming IPOsPrivate market basicsPrivate shares transactionsValuations, pricing and market trendsSelling in the private marketFAQsGlossaryCompany page and tradesProof of ownershipBid and ask submissionsForge fund offeringsInsights About UsLeadershipInvestor RelationsPeople & CultureCareers About
Log InSign Up
Who We Serve
What We Do
Insights
About
Who We Serve
Individual Investors
Institutional Investors
What We Do
Trading
Individual Investing
Institutional Trading
Data
Liquidity Programs
Retirement
Self-Directed IRA
Insights
Reports and highlights
News and trends
Private market education
Tips and tutorials
About
Log In
Sign Up
Secondary marketplace / Trade private companies / Buy and sell Carmot Therapeutics stock
Carmot Therapeutics

Carmot Therapeutics stock

Highest bid
$XXXX
x/xx/xx
Lowest ask
$XXXX
x/xx/xx
Last matched price
$XXXX
x/xx/xx
Forge Price 1
$--
Buy And Sell Carmot Therapeutics StockLearn More About Carmot Therapeutics IPOAdd To Watchlist
Register to buy and sell private company shares
For more details on private stock price information, financing and valuation for Carmot Therapeutics, register or log in.
Please provide a valid email address.
By registering, you agree to Forge’s Terms of Use. Already registered? Log In

Carmot Therapeutics stock price

Trade metrics

Market activity 2
Limited
Active bids
XX
Active asks
XX
Highest bid price
$ XXX.XX
Lowest ask price
$ XXX.XX
Total bids
$XXX
Total asks
$XXX
Last matched price
$ XXX.XX
xx/xx/xxxx
Last matched valuation
$ XXX.XX
xx/xx/xxxx
Access Stock Price

Price history chart

7D
1M
3M
1Y
All
Forge Price
$--
Not yet available
Forge Price valuation
$--
Forge Price
Bids
Asks
The image displayed is not current and any securities shown are for illustrative purposes only.

Actively traded Healthcare companies

Neuralink Neuralink
See All Actively Traded Companies

Active market

Active market Explore Market Activity
The image displayed is not current and any securities shown are for illustrative purposes only.

Forge exclusive fund offerings

Fund offerings
The image displayed is not current and any securities shown are for illustrative purposes only.
Forge exclusive fund offerings
Access high-growth companies at a fixed price—for a limited time
Invest in trending companies with lower minimums
Simplify private investing through a Forge-managed single company fund
See Available Offerings

Carmot Therapeutics stock FAQs

To buy and sell Carmot Therapeutics stock

Can you buy Carmot Therapeutics stock?

As Carmot Therapeutics is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like Carmot Therapeutics, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge to buy private market stock on our secondary marketplace. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.

How to buy Carmot Therapeutics stock?

To invest in a private company like Carmot Therapeutics through Forge, you must first qualify as an accredited investor. Create your account. Verify your identity and accreditation status to access Forge’s real-time marketplace.

  1. Explore opportunities. Browse companies with active bids and asks, plus data-driven pricing insights like historical trades and Forge Price™.
  2. Submit or negotiate a bid. Place a bid or engage with existing asks—self-directed and fully transparent.
  3. Complete your trade. Forge handles paperwork and approvals, with settlement typically in 45-60 days.
If you’d like additional guidance, Forge private market specialists are available to help.

Can you sell Carmot Therapeutics stock?

Yes, as a shareholder, you may be able to sell your Carmot Therapeutics shares through Forge’s private market platform—subject to company policies and market interest.

To get started:

  1. Create a Forge account and complete identity and ownership verification.
  2. Submit a sell order (ask) by specifying your desired price, quantity and share class.
  3. Forge will work to match your order with interested buyers in the marketplace.
  4. If a match occurs, Forge coordinates the necessary company approvals and compliance checks, including any transfer restrictions or right of first refusal (ROFR) processes Carmot Therapeutics may have in place.
Please note that the ability to complete a transaction depends on Carmot Therapeutics’ secondary trading policies, available demand and transaction approvals. While liquidity is not guaranteed, listing your shares on Forge allows you to signal interest and potentially connect with qualified buyers.

How to sell Carmot Therapeutics stock?

  1. Create a free Forge account to access Forge’s next generation marketplace
  2. Explore potential demand for your shares and view live market interest
  3. Use proprietary pricing insights and market data to assess timing and valuation
  4. Submit an indication to sell, negotiate terms, complete the transaction and receive your payment

To learn more about Carmot Therapeutics stock

Is Carmot Therapeutics a public company?

No, Carmot Therapeutics is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.

What is Carmot Therapeutics’ stock price?

Carmot Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Carmot Therapeutics private market stock price with Forge Data.

What is Carmot Therapeutics’ stock ticker symbol?

Carmot Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Carmot Therapeutics funding rounds and valuation

Total funding $594.61MM

Funding history chart

Funding round details

Funding Date Share Class Amount Raised Price Per Share Post-Money Valuation 3 Key Investors
05/25/2023 Series E $150MM $23.01 $696.68MM 5am Ventures, Deep Track Capital, Franklin Templeton, Frazier Life Sciences, Janus Henderson Investors, Millenium Management, Ra Capital Management, Tcgx, The Column Group, Venrock Healthcare Capital Partners, Willett Advisors
Price Per Share
$23.01
Shares Outstanding
6,519,392
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
5am Ventures, Deep Track Capital, Franklin Templeton, Frazier Life Sciences, Janus Henderson Investors, Millenium Management, Ra Capital Management, Tcgx, The Column Group, Venrock Healthcare Capital Partners, Willett Advisors
08/26/2022 Series D $130.44MM $19.19 $464.88MM Deep Track Capital, Horizons Ventures, Ra Capital Management, The Column Group, Willett Advisors
Price Per Share
$19.19
Shares Outstanding
6,798,176
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Deep Track Capital, Horizons Ventures, Ra Capital Management, The Column Group, Willett Advisors
08/26/2022 Series D-1 $30.23MM $16.31 $464.88MM Deep Track Capital, Horizons Ventures, Ra Capital Management, The Column Group, Willett Advisors
Price Per Share
$16.31
Shares Outstanding
1,853,391
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Deep Track Capital, Horizons Ventures, Ra Capital Management, The Column Group, Willett Advisors
09/30/2020 Series C $46.88MM $14.58 $179.66MM Amgen Ventures, Horizons Ventures, The Column Group
Price Per Share
$14.58
Shares Outstanding
3,215,335
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Amgen Ventures, Horizons Ventures, The Column Group
01/17/2018 Series B $12.59MM $6.37 $57.39MM Horizons Ventures, Jerome Dahan, The Column Group
Price Per Share
$6.37
Shares Outstanding
1,977,878
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Horizons Ventures, Jerome Dahan, The Column Group
04/07/2010 Series A $2.16MM $0.63 $4.8MM Undisclosed Investors
Price Per Share
$0.63
Shares Outstanding
3,431,745
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors

Company details

Carmot Therapeutics is focused on the discovery and development of disease-modifying therapies for patients living with metabolic diseases and cancer. Carmot applies Chemotype Evolution (CE), a pioneering drug discovery platform, in combination with unique biological expertise to identify innovative and superior therapeutics.
carmot-therapeutics.us
Sector
Healthcare
Subsector
Biotech & Pharma
Founded
2008
Headquarters
Berkeley, CA, United States
Leadership
Heather Turner
Chief Executive Office
Manu Cakravarthy, MD, PhD
Chief Medical & Scienctific
Michael Gray
Chief Operating Officer

Carmot Therapeutics news and media highlights

QuotedData 12/08/2023

Schroders Capital Global Innovation’s Carmot Therapeutics sold to Roche

Schroders Capital Global Innovation (INOV) has announced that its portfolio company Carmot Therapeutics Inc., a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases including obesity and diabetes, entered into a definitive agreement to be acquired by Roche, on 3 December 2023. Roche is acquiring Carmot at a purchase price of US$2.7 billion upfront with the potential for US$400 million in milestone payments. The agreement is expected to close in the first quarter of 2024, subject to customary closing conditions and required regulatory approvals. INOV says that full details of its profit on the sale will be released in due course.
Wealth of Geeks 12/01/2023

Carmot Readies IPO to Seize Bulging Obesity and Diabetes Market

Gloomy clouds may still hang thick over the initial public offering (IPO) market, but some companies are still wading into the listing abyss. Investors seeking a new biopharma play have a new deal to size up. On November 20, Carmot Therapeutics filed its paperwork with the Securities and Exchange Commission (SEC) for its debut in public markets. The firm has not yet released price details for the deal; instead, it is citing the placeholder sum of $100 million in its submitted documentation. The company hopes to list its shares on Nasdaq “as soon as practicable after this registration” under the ticker “CRMO.”
FinSMEs 05/31/2023

Carmot Therapeutics Raises $150M in Series E Equity Financing

Carmot Therapeutics, a Berkeley, CA-based clinical-stage biotechnology company, raised $150M in Series E funding. The round was led by Deep Track Capital with participation from 5AM Ventures, Franklin Templeton, Frazier Life Sciences, Janus Henderson Investors, RA Capital Management, Millennium Management, TCGX, The Column Group, Venrock Healthcare Capital Partners and Willett Advisors.
Browse More Insights

Other companies like Carmot Therapeutics in the Biotech & Pharma sector

Sector: Healthcare
Subsector: Biotech & Pharma
Trade Metrics Last Funding Round
Company Forge Price Last Matched Price Share Class Post-Money Valuation 3 Price Per Share Amount Raised
Altos LabsAltos Labs--$xx.xxSeries C$6.33B$25.02$1.5B
ApnimedApnimed--$xx.xxSeries D$394.07MM$9.65$16.5MM
Colossal BiosciencesColossal Biosciences--$xx.xxSeries C$10.2B$24.89$200MM
Generate:BiomedicinesGenerate:Biomedicines--$xx.xxSeries C$1.95B$11.85$288MM
Human LongevityHuman Longevity--$xx.xxSeries B-1$185.79MM$0.31$32MM
Isomorphic LabsIsomorphic Labs--$xx.xx--------
LoyalLoyal--$xx.xxSeries B-5$428.44MM$10.64$17.49MM
OwkinOwkin--$xx.xxSeries B-1$1.46B$45.70$50MM
Precision NeurosciencePrecision Neuroscience--$xx.xxSeries C$542.69MM$5.70$102MM
Seaport TherapeuticsSeaport Therapeutics--$xx.xxSeries B$734.14MM$4.75$226MM
See All Companies

Forge is your trusted partner to buy and sell Carmot Therapeutics stock

Forge is the trusted platform for buying and selling private company stock. Investors and shareholders worldwide rely on our deep data insights, liquidity solutions, and tailored investment opportunities to navigate the private market. Register to get started.

Register

Updated on: Jul 16, 2025

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

  1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
  2. Market activity indicates the level of activity for a company based on recent IOIs, secondary transactions, and pending transactions.
  3. Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
  4. Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
  5. Most active companies are companies with a high market activity with the highest post-money valuation in the same sector.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

The news articles displayed on this page may be curated using artificial intelligence (AI) technology, which selects relevant content from a list of trusted web sources. While we strive for accuracy and reliability, the inclusion of an article does not imply endorsement or verification of its content. This communication is for informational purposes only. Investors should conduct their own research and consult a financial professional before making investment decisions.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.